 |
|
ABOUT US |  |
INVESTMENT PORTFOLIO |  |
OUR TEAM | |
BOARD OF DIRECTORS | |
INVESTMENT STRATEGY | |
NEWS | |
|
INVESTOR LOGIN | |
CONTACT | |
HOME | |
|
|
 |
 |
 |
Action Pharma A/S Action Pharma is a biotech company founded in year 2000 and located just north of Copenhagen, Denmark. Action Pharma pursues the discovery and development of drug candidates within cardiovascular diseases, inflammatory diseases and Type II diabetes. Action Pharma now has a pipeline of seven drug candidates of which two are in clinical development phase in Scandinavia and in the USA. Go to website >> |
|
 |
AdvanDx Inc AdvanDx is a molecular diagnostic company committed to provide the medical profession with advanced in vitro diagnostic kits, such as PNA FISH for rapid and simple pathogen identification in blood cultures and screening test for the prevention of hospital acquired infections, leading to improved therapy and better patient management. AdvanDx was founded in 2002 by Mr. Thais T. Johansen, President and CEO, and Dr. Henrik Stender, Vice President of Research and Development Go to website >> |
|
 |
Aerocrine AB Aerocrine AB is a clinically based medical/technical company with headquarters in Stockholm, Sweden. It was founded in 1997 by scientists at the Karolinska Institute. They were among the first to identify the involvement of Nitric Oxide (NO) in inflammation. Aerocrine develops and commercializes products for the monitoring of NO as a marker of inflammation, to improve the management and care of patients with inflammatory disease in the airways. Aerocrine has released NIOX® and NIOXMINO®, the first tailor-made NO-analyzers for routine clinical use with asthma patients. Go to website >> |
|
 |
Angio Genetics AB Angio Genetics AB is an early stage drug discovery company located at the Karolinska Institute. The technology base of the company is angiogenesis, the formation of new blood vessels. The company was incorporated in June 2001 as a spin-out from Gothenburg University and the Karolinska Institute. The focus of Angio Genetics AB is in the area of angiogenesis regulation, and for diseases, in which pro- or anti-angiogenic therapy potentially could have a strong clinical impact, such as cancer and ischemic heart disease. Go to website >> |
|
 |
Atlas Antibodies AB |
|
 |
Biopheresis Technologies GmbH Biopheresis Technologies is developing an innovative immuno/biological therapy, utilizing a patented medical device product, initially focused on cancer indications. The company was founded and is incorporated in the US, but is operationally centered in Heidelberg, Germany, where, through its wholly-owned German GmbH subsidiary, the company is planning post-marketing clinical studies in metastatic breast cancer patients. Go to website >> |
|
 |
Doxa AB Doxa AB is a Swedish R&D company located at the university city of Uppsala. Doxa's business model is to develop, manufacture and commercialize innovative products based upon its unique patented technology platform of calcium aluminate hydrate and bioactive ceramics. The bioactive feature enables an immediate chemical integration between the ceramic material and the hard tissue in the body, resulting in several unique clinical advantages. Key therapy areas are Spine, other Orthopaedics and Dental. |
|
 |
Exiqon A/S |
|
 |
Gyros AB Gyros AB is world leader in the miniaturization and integration of laboratory applications through its proprietary microfluidics platform, Gyrolab CD (compact disc) microlaboratory. Gyros delivers simple to use, precisely controlled solutions for processing hundreds of samples in parallel at nanoliter scale. Scientists are able to use immunoassays with a very broad measuring range to generate more information from less sample and improve productivity and efficiency. The company is currently focused on two market segments: quantitative protein analysis for research, drug discovery and development applications; and, in vitro diagnostics for medical applications. Gyros has more than 45 employees working at its headquarters and European sales office in Uppsala, Sweden and its sales office in the USA. Go to website >> |
|
 |
Light Sciences Oncology, Inc. |
|
 |
MetaCure Limited |
|
 |
MILLiMED Holdings Inc. MILLiMED develops therapeutic devices used in advanced endothelial management based on its technology platform enabling local delivery of Nitric Oxide by way of minimal invasive procedures. Go to website >> |
|
 |
Nuevolution A/S
Nuevolution A/S is a drug discovery company based on its proprietary Chemetics™ technologies to rapidly identify multiple drug candidates to virtually any target in very short time. |
|
 |
Oncolog Medical ONCOlog Medical is a medical technology company developing unique products and solutions for safer and more cost-effective radiation therapy of various tumor diseases. The product portfolio includes patient handling and positioning systems, treatment table tops and quality assurance systems. Go to website >> |
|
 |
Orexo AB Orexo AB is a pharmaceutical company that focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them. Orexo has a balanced portfolio with two products on the market, three in registration and/or late stage clinical phase, one in clinical phase I, one in formulation phase and two in early development phase. Go to website >> |
|
 |
OxThera OxThera is a clinical stage biotechnology company based in Sweden and Florida. The company develops products, based on its cell- and enzyme based proprietary technologies, for metabolic disorders based on excess oxalate from endogenous and exogenous sources. OxThera will market and sell its orphan drug products to treat and prevent hyperoxaluria and kidney stones in indications such as Primary and Enteric Hyperoxaluria. Go to website >> |
|
 |
PreciSense A/S PreciSense A/S is developing a novel, minimally invasive measurement device of blood glucose for diabetic patients. The global market for diabetes is large and growing rapidly. A key component of modern diabetes care is to maintain metabolic control, which is facilitated by increased awareness of glucose levels. The PreciSense glucose monitoring system is currently entering clinical trials and aims to target both the discrete and continuous markets. Go to website >> |
|
 |
Sanos Bioscience A/S Sanos Bioscience A/S is a spin-out from Nordic Bioscience A/S focusing on development of GLP-2 for the treatment of osteoporosis. Go to website >> |
|
 |
Sophion Bioscience A/S Sophion Bioscience A/S is committed to providing advanced products and integrated solutions for high-throughput ion channel characterization of living cells. Their products and solutions fulfill a growing demand from the pharmaceutical industry for faster screening methods with much higher information content than today. This enables faster development of new and better drugs. Go to website >> |
|
 |
Symphogen A/S |
|